5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Monitor O
patients O
with O
benign O
prostatic O
hyperplasia O
( O
BPH O
) O
for O
worsening O
of O
signs O
and O
symptoms O
of O
BPH O
. O

( O
5.1 O
) O
* O
Avoid O
unintentional O
exposure O
of O
women O
or O
children O
to O
AndroGel O
1 O
% O
. O

Secondary O
exposure O
to O
testosterone O
can O
produce O
signs O
of O
virilization O
. O

AndroGel O
1 O
% O
should O
be O
discontinued O
until O
the O
cause O
of O
virilization O
is O
identified O
. O

( O
5.2 O
) O
* O
Venous O
thromboembolism O
( O
VTE O
) O
, O
including O
deep O
vein O
thrombosis O
( O
DVT O
) O
and O
pulmonary O
embolism O
( O
PE O
) O
have O
been O
reported O
in O
patients O
using O
testosterone O
products O
. O

Evaluate O
patients O
with O
signs O
or O
symptoms O
consistent O
with O
DVT O
or O
PE O
. O

( O
5.4 O
) O
* O
Some O
postmarketing O
studies O
have O
shown O
an O
increased O
risk O
of O
myocardial O
infarction O
and O
stroke O
associated O
with O
use O
of O
testosterone O
replacement O
therapy O
. O

( O
5.5 O
) O
* O
Exogenous O
administration O
of O
androgens O
may O
lead O
to O
azoospermia O
. O

( O
5.8 O
) O
* O
Edema O
, O
with O
or O
without O
congestive O
heart O
failure O
( O
CHF O
) O
, O
may O
be O
a O
complication O
in O
patients O
with O
preexisting O
cardiac O
, O
renal O
, O
or O
hepatic O
disease O
. O

( O
5.10 O
, O
6.2 O
) O
* O
Sleep O
apnea O
may O
occur O
in O
those O
with O
risk O
factors O
. O

( O
5.12 O
) O
* O
Monitor O
serum O
testosterone O
, O
prostate O
specific O
antigen O
( O
PSA O
) O
, O
hemoglobin O
, O
hematocrit O
, O
liver O
function O
tests O
, O
and O
lipid O
concentrations O
periodically O
. O

( O
5.1 O
, O
5.3 O
, O
5.9 O
, O
5.13 O
) O
* O
AndroGel O
1 O
% O
is O
flammable O
until O
dry O
. O

( O
5.16 O
) O
5.1 O
Worsening O
of O
Benign O
Prostatic O
Hyperplasia O
( O
BPH O
) O
and O
Potential O
Risk O
of O
Prostate O
Cancer O
* O
Patients O
with O
BPH B-Not_AE_Candidate
treated O
with O
androgens O
are O
at O
an O
increased O
risk O
for O
worsening B-OSE_Labeled_AE
of O
signs O
and O
symptoms O
of O
BPH I-OSE_Labeled_AE
. O

Monitor O
patients O
with O
BPH B-Not_AE_Candidate
for O
worsening O
signs O
and O
symptoms O
. O

* O
Patients O
treated O
with O
androgens O
may O
be O
at O
increased O
risk O
for O
prostate B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
. O

Evaluate O
patients O
for O
prostate B-NonOSE_AE
cancer I-NonOSE_AE
prior O
to O
initiating O
and O
during O
treatment O
with O
androgens O
[ O
see O
Contraindications O
( O
4 O
) O
, O
Adverse O
Reactions O
( O
6.1 O
) O
and O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
. O

5.2 O
Potential O
for O
Secondary O
Exposure O
to O
Testosterone O
Cases O
of O
secondary B-OSE_Labeled_AE
exposure I-OSE_Labeled_AE
resulting O
in O
virilization O
of O
ch O
ildren B-OSE_Labeled_AE
  I-OSE_Labeled_AE
I I-OSE_Labeled_AE
- I-OSE_Labeled_AE
OSE I-OSE_Labeled_AE
_Labeled_AE O
have O
been O
reported O
in O
postmarketing O
surveillance O
. O

Signs O
and O
symptoms O
have O
included O
enlargement B-NonOSE_AE
of I-NonOSE_AE
the O
penis O
or O
clitoris I-NonOSE_AE
, O
development B-NonOSE_AE
of I-NonOSE_AE
pubic I-NonOSE_AE
hair I-NonOSE_AE
, O
increased B-NonOSE_AE
erections I-NonOSE_AE
and O
libido O
, O
aggressive B-NonOSE_AE
behavior I-NonOSE_AE
, O
and O
advanced B-NonOSE_AE
bone I-NonOSE_AE
age I-NonOSE_AE
. O

In O
most O
cases O
, O
these O
signs O
and O
symptoms O
regressed O
with O
removal O
of O
the O
exposure O
to O
testosterone O
gel O
. O

In O
a O
few O
cases O
, O
however O
, O
enlarged B-NonOSE_AE
genitalia I-NonOSE_AE
did O
not O
fully O
return O
to O
age-appropriate O
normal O
size O
, O
and O
bone B-NonOSE_AE
age I-NonOSE_AE
remained I-NonOSE_AE
modestly I-NonOSE_AE
greater I-NonOSE_AE
than O
chronological O
age O
. O

The O
risk O
of O
transfer O
was O
increased O
in O
some O
of O
these O
cases O
by O
not O
adhering O
to O
precautions O
for O
the O
appropriate O
use O
of O
the O
topical O
testosterone O
product O
. O

Children O
and O
women O
should O
avoid O
contact O
with O
unwashed O
or O
unclothed O
application O
sites O
in O
men O
using O
AndroGel O
1 O
% O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
and O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

Inappropriate O
changes B-NonOSE_AE
in I-NonOSE_AE
genital I-NonOSE_AE
size I-NonOSE_AE
or O
development O
of O
pubic O
hair O
or O
libido O
in I-NonOSE_AE
children I-NonOSE_AE
, O
or O
changes B-NonOSE_AE
in I-NonOSE_AE
body I-NonOSE_AE
hair I-NonOSE_AE
distribution I-NonOSE_AE
, O
significant O
increase O
in O
acne B-NonOSE_AE
, O
or O
other O
signs O
of O
virilization B-NonOSE_AE
in O
adult O
women O
should O
be O
brought O
to O
the O
attention O
of O
a O
physician O
and O
the O
possibility O
of O
secondary B-NonOSE_AE
exposure I-NonOSE_AE
to I-NonOSE_AE
testosterone I-NonOSE_AE
gel I-NonOSE_AE
should O
also O
be O
brought O
to O
the O
attention O
of O
a O
physician O
. O

Testosterone O
gel O
should O
be O
promptly O
discontinued O
until O
the O
cause O
of O
virilization B-NonOSE_AE
has O
been O
identified O
. O

5.3 O
Polycythemia B-OSE_Labeled_AE
Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hematocrit I-OSE_Labeled_AE
, O
reflective O
of O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
red I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
mass I-OSE_Labeled_AE
, O
may O
require O
lowering O
or O
discontinuation O
of O
testosterone O
. O

Check O
hematocrit O
prior O
to O
initiating O
treatment O
. O

It O
would O
also O
be O
appropriate O
to O
re-evaluate O
the O
hematocrit O
3 O
to O
6 O
months O
after O
starting O
treatment O
, O
and O
then O
annually O
. O

If O
hematocrit B-NonOSE_AE
becomes I-NonOSE_AE
elevated I-NonOSE_AE
, O
stop O
therapy O
until O
hematocrit B-NonOSE_AE
decreases I-NonOSE_AE
to O
an O
acceptable O
concentration O
. O

An O
increase B-NonOSE_AE
in I-NonOSE_AE
red I-NonOSE_AE
blood I-NonOSE_AE
cell I-NonOSE_AE
mass I-NonOSE_AE
may O
increase O
the O
risk O
of O
thromboembolic B-NonOSE_AE
events I-NonOSE_AE
. O

5.4 O
Venous O
Thromboembolism O
There O
have O
been O
postmarketing O
reports O
of O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
including O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
( I-OSE_Labeled_AE
DVT I-OSE_Labeled_AE
) O
and O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PE I-OSE_Labeled_AE
) O
, O
in O
patients O
using O
testosterone O
products O
such O
as O
AndroGel O
1 O
% O
. O

Evaluate O
patients O
who O
report O
symptoms O
of O
pain B-NonOSE_AE
, O
edema O
, O
warmth O
and O
erythema O
in I-NonOSE_AE
the O
lower I-NonOSE_AE
extremity I-NonOSE_AE
for O
DVT B-NonOSE_AE
and O
those O
who O
present O
with O
acute O
shortness B-NonOSE_AE
of I-NonOSE_AE
breath I-NonOSE_AE
for O
PE B-NonOSE_AE
. O

If O
a O
venous B-NonOSE_AE
thromboembolic I-NonOSE_AE
event I-NonOSE_AE
is O
suspected O
, O
discontinue O
treatment O
with O
AndroGel O
1 O
% O
and O
initiate O
appropriate O
workup O
and O
management O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

5.5 O
Cardiovascular O
Risk O
Long O
term O
clinical O
safety O
trials O
have O
not O
been O
conducted O
to O
assess O
the O
cardiovascular O
outcomes O
of O
testosterone O
replacement O
therapy O
in O
men O
. O

To O
date O
, O
epidemiologic O
studies O
and O
randomized O
controlled O
trials O
have O
been O
inconclusive O
for O
determining O
the O
risk O
of O
major B-NonOSE_AE
adverse I-NonOSE_AE
cardiovascular I-NonOSE_AE
events I-NonOSE_AE
( I-NonOSE_AE
MACE I-NonOSE_AE
) O
, O
such O
as O
non-fatal O
myocardial B-NonOSE_AE
infarction I-NonOSE_AE
, O
non-fatal O
stroke B-NonOSE_AE
, O
and O
cardiovascular B-NonOSE_AE
death I-NonOSE_AE
, O
with O
the O
use O
of O
testosterone O
compared O
to O
non-use O
. O

Some O
studies O
, O
but O
not O
all O
, O
have O
reported O
an O
increased O
risk O
of O
MACE B-OSE_Labeled_AE
in O
association O
with O
use O
of O
testosterone O
replacement O
therapy O
in O
men O
. O

Patients O
should O
be O
informed O
of O
this O
possible O
risk O
when O
deciding O
whether O
to O
use O
or O
to O
continue O
to O
use O
AndroGel O
1 O
% O
. O

5.6 O
Abuse O
of O
Testosterone O
and O
Monitoring O
of O
Serum O
Testosterone O
Concentrations O
Testosterone O
has O
been O
subject O
to O
abuse B-OSE_Labeled_AE
, O
typically O
at O
doses O
higher O
than O
recommended O
for O
the O
approved O
indication O
and O
in O
combination O
with O
other O
anabolic O
androgenic O
steroids O
. O

Anabolic O
androgenic O
steroid O
abuse B-NonOSE_AE
can O
lead O
to O
serious O
cardiovascular B-NonOSE_AE
and O
psychiatric O
adverse I-NonOSE_AE
reactions I-NonOSE_AE
[ O
see O
Drug O
Abuse O
and O
Dependence O
( O
9 O
) O
] O
. O

If O
testosterone O
abuse B-NonOSE_AE
is O
suspected O
, O
check O
serum O
testosterone O
concentrations O
to O
ensure O
they O
are O
within O
therapeutic O
range O
. O

However O
, O
testosterone O
levels O
may O
be O
in O
the O
normal O
or O
subnormal O
range O
in O
men O
abusing O
synthetic O
testosterone O
derivatives O
. O

Counsel O
patients O
concerning O
the O
serious O
adverse O
reactions O
associated O
with O
abuse B-NonOSE_AE
of O
testosterone O
and O
anabolic O
androgenic O
steroids O
. O

Conversely O
, O
consider O
the O
possibility O
of O
testosterone O
and O
anabolic O
androgenic O
steroid O
abuse B-NonOSE_AE
in O
suspected O
patients O
who O
present O
with O
serious O
cardiovascular B-NonOSE_AE
or O
psychiatric O
adverse I-NonOSE_AE
events I-NonOSE_AE
. O

5.7 O
Use O
in O
Women O
Due O
to O
lack O
of O
controlled O
evaluations O
in O
women O
and O
potential O
virilizing B-NonOSE_AE
effects I-NonOSE_AE
, O
AndroGel O
1 O
% O
is O
not O
indicated O
for O
use O
in O
women O
[ O
see O
Contraindications O
( O
4 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.1 O
, O
8.3 O
) O
] O
. O

5.8 O
Potential O
for O
Adverse O
Effects O
on O
Spermatogenesis O
With O
large O
doses O
of O
exogenous O
androgens O
, O
including O
AndroGel O
1 O
% O
, O
spermatogenesis B-OSE_Labeled_AE
may I-OSE_Labeled_AE
be I-OSE_Labeled_AE
suppressed I-OSE_Labeled_AE
through O
feedback O
inhibition O
of O
pituitary O
follicle-stimulating O
hormone O
( O
FSH O
) O
which O
could O
possibly O
lead O
to O
adverse B-OSE_Labeled_AE
effects I-OSE_Labeled_AE
on I-OSE_Labeled_AE
semen I-OSE_Labeled_AE
parameters I-OSE_Labeled_AE
including I-OSE_Labeled_AE
sperm I-OSE_Labeled_AE
count I-OSE_Labeled_AE
. O

5.9 O
Hepatic O
Adverse O
Effects O
Prolonged O
use O
of O
high O
doses O
of O
orally O
active O
17-alpha-alkyl O
androgens O
( O
e.g. O
, O
methyltestosterone O
) O
has O
been O
associated O
with O
serious O
hepatic B-NonOSE_AE
adverse I-NonOSE_AE
effects I-NonOSE_AE
( O
peliosis B-NonOSE_AE
hepatis I-NonOSE_AE
, O
hepatic B-NonOSE_AE
neoplasms I-NonOSE_AE
, O
cholestatic B-NonOSE_AE
hepatitis I-NonOSE_AE
, O
and O
jaundice B-NonOSE_AE
) O
. O

Peliosis B-NonOSE_AE
hepatis I-NonOSE_AE
can O
be O
a O
life-threatening O
or O
fatal O
complication O
. O

Long-term O
therapy O
with O
intramuscular O
testosterone O
enanthate O
has O
produced O
multiple O
hepatic B-NonOSE_AE
adenomas I-NonOSE_AE
. O

AndroGel O
1 O
% O
is O
not O
known O
to O
cause O
these O
adverse O
effects O
. O

5.10 O
Edema O
Androgens O
, O
including O
AndroGel O
1 O
% O
, O
may O
promote O
retention B-OSE_Labeled_AE
of I-OSE_Labeled_AE
sodium O
and O
water I-OSE_Labeled_AE
. O

Edema B-OSE_Labeled_AE
, O
with O
or O
without O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
may O
be O
a O
serious O
complication O
in O
patients O
with O
preexisting O
cardiac B-Not_AE_Candidate
, O
renal O
, O
or O
hepatic O
disease I-Not_AE_Candidate
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

5.11 O
Gynecomastia O
Gynecomastia B-OSE_Labeled_AE
may O
develop O
and O
persist O
in O
patients O
being O
treated O
with O
androgens O
, O
including O
AndroGel O
1 O
% O
, O
for O
hypogonadism B-Not_AE_Candidate
. O

5.12 O
Sleep O
Apnea O
The O
treatment O
of O
hypogonadal B-Not_AE_Candidate
men O
with O
testosterone O
may O
potentiate O
sleep B-OSE_Labeled_AE
apnea I-OSE_Labeled_AE
in O
some O
patients O
, O
especially O
those O
with O
risk O
factors O
such O
as O
obesity B-Not_AE_Candidate
or O
chronic B-Not_AE_Candidate
lung I-Not_AE_Candidate
diseases I-Not_AE_Candidate
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

5.13 O
Lipids O
Changes B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
lipid I-OSE_Labeled_AE
profile I-OSE_Labeled_AE
may O
require O
dose O
adjustment O
or O
discontinuation O
of O
testosterone O
therapy O
. O

5.14 O
Hypercalcemia B-OSE_Labeled_AE
Androgens O
, O
including O
AndroGel O
1 O
% O
, O
should O
be O
used O
with O
caution O
in O
cancer B-Not_AE_Candidate
patients I-Not_AE_Candidate
at O
risk O
of O
hypercalcemia B-Not_AE_Candidate
( O
and O
associated O
hypercalciuria B-Not_AE_Candidate
) O
. O

Regular O
monitoring O
of O
serum B-NonOSE_AE
calcium I-NonOSE_AE
concentrations O
is O
recommended O
in O
these O
patients O
. O

5.15 O
Decreased O
Thyroxine-binding O
Globulin O
Androgens O
, O
including O
AndroGel O
1 O
% O
, O
may O
decrease B-OSE_Labeled_AE
concentrations I-OSE_Labeled_AE
of I-OSE_Labeled_AE
thyroxin I-OSE_Labeled_AE
- I-OSE_Labeled_AE
binding I-OSE_Labeled_AE
globulins I-OSE_Labeled_AE
, O
resulting O
in O
decreased B-OSE_Labeled_AE
total I-OSE_Labeled_AE
T I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
concentrations I-OSE_Labeled_AE
and O
increased B-OSE_Labeled_AE
resin I-OSE_Labeled_AE
uptake I-OSE_Labeled_AE
of I-OSE_Labeled_AE
T3 O
and O
T I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
. O

Free O
thyroid O
hormone O
concentrations O
remain O
unchanged O
, O
however O
, O
and O
there O
is O
no O
clinical O
evidence O
of O
thyroid B-NonOSE_AE
dysfunction I-NonOSE_AE
. O

5.16 O
Flammability O
Alcohol O
based O
products O
, O
including O
AndroGel O
1 O
% O
, O
are O
flammable O
; O
therefore O
, O
patients O
should O
be O
advised O
to O
avoid O
fire O
, O
flame O
or O
smoking O
until O
the O
AndroGel O
1 O
% O
has O
dried O
. O

